Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines.
about
ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signalingHigh mobility group A2 protein and its derivatives bind a specific region of the promoter of DNA repair gene ERCC1 and modulate its activityIdentification of semaphorin E as a non-MDR drug resistance gene of human cancersBiomarkers of head and neck cancer, tools or a gordian knot?Crystal structure of a double-stranded DNA containing a cisplatin interstrand cross-link at 1.63 A resolution: hydration at the platinated siteKRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cellsPhotoaffinity labeling reveals nuclear proteins that uniquely recognize cisplatin-DNA interstrand cross-linksDecreased transcription-coupled nucleotide excision repair capacity is associated with increased p53- and MLH1-independent apoptosis in response to cisplatin.Up-regulation of Fas reverses cisplatin resistance of human small cell lung cancer cellsIn vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubulesLipid replacement therapy: a nutraceutical approach for reducing cancer-associated fatigue and the adverse effects of cancer therapy while restoring mitochondrial function.Transcriptional activation and cell cycle block are the keys for 5-fluorouracil induced up-regulation of human thymidylate synthase expression.Reversing mitochondrial dysfunction, fatigue and the adverse effects of chemotherapy of metastatic disease by molecular replacement therapy.Role of the human ERCC-1 gene in gene-specific repair of cisplatin-induced DNA damage.Cisplatin loaded albumin mesospheres for lung cancer treatment.DNA double helix promotes a linkage isomerization reaction in trans-diamminedichloroplatinum(II)-modified DNA.Rapid gene-specific repair of cisplatin lesions at the human DUG/DHFR locus comprising the divergent upstream gene and dihydrofolate reductase gene during early G1 phase of the cell cycle assayed by using the exonucleolytic activity of T4 DNA polymeRepair synthesis by human cell extracts in cisplatin-damaged DNA is preferentially determined by minor adductsChemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness.Characterisation of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: cross-resistance and protein changesNucleotide excision repair and anti-cancer chemotherapyDNA interstrand cross-links of trans-diamminedichloroplatinum(II) are preferentially formed between guanine and complementary cytosine residuesGene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatinVisualizing inhibition of nucleosome mobility and transcription by cisplatin-DNA interstrand crosslinks in live mammalian cellsβ-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNKReduced endocytosis and altered lysosome function in cisplatin-resistant cell linesDNA damage by anti-cancer agents resolved at the nucleotide level of a single copy gene: evidence for a novel binding site for cisplatin in cells.MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2.Exploring biomarkers in head and neck cancer.A human factor that recognizes DNA substituted with 2-chloroadenine, an antileukemic purine analog.A confidence building exercise in data and identifiability: Modeling cancer chemotherapy as a case study.Four mononuclear platinum(II) complexes: synthesis, DNA/BSA binding, DNA cleavage and cytotoxicity.Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.Rearrangement of interstrand cross-links into intrastrand cross-links in cis-diamminedichloroplatinum(II)-modified DNA.High definition cytogenetics and oligonucleotide aCGH analyses of cisplatin-resistant ovarian cancer cells.In vitro antitumor activity of 2-acetyl pyridine 4n-ethyl thiosemicarbazone and its platinum(II) and palladium(II) complexes.Base sequence-independent distorsions induced by interstrand cross-links in cis-diamminedichloroplatinum (II)-modified DNA.Intragenomic heterogeneity of DNA damage formation and repair: a review of cellular responses to covalent drug DNA interaction.DNA-crosslinker cisplatin eradicates bacterial persister cells.Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II): therapeutic implications.
P2860
Q21131951-57ABB174-1F26-418F-9C85-513F03E138E4Q24300124-3ACA5ADB-F890-48B9-953E-4C83F606BE75Q24315145-C460F87D-ED18-41DA-8E39-9640B9A4682BQ26784289-4C868190-566B-468D-97ED-8810A21558FCQ27617786-F35E6171-13E1-449B-B579-22ED897B24D3Q28485355-C7862F8F-B061-43D3-AF50-C3BD6D7472A2Q33429678-E89A9F76-7764-4AD0-89BE-98737BE7D9A5Q33578400-0C172DD1-F776-4D44-83DB-FC24CF006590Q33878705-0D9C7610-6216-47D1-95A2-95A31C8CBA07Q34114078-CC455678-174A-4F68-9D2F-F8323757F12BQ34131833-360D2696-94CE-4275-A0A3-5E02EFF633ACQ34443004-185864A1-0C98-49F4-BADA-8825F5F33F96Q34721743-E69EA125-2AD7-4D36-933C-F3551A57428BQ35009287-C4C15600-14ED-4B54-9067-ADAC7B14652BQ35402288-F1520D1E-8561-45E4-9F2F-90AC631CA374Q35685036-3960A5D4-0970-4B6E-995E-D5B097D076ABQ35888670-090CE211-3925-4DEE-AD23-11605BA3F290Q35936892-1B35B9BC-70BA-4B5D-84C3-CA811787D9D4Q35937785-7C04E3D8-AFA7-45F3-9349-697AF664791FQ36080744-E4A33C45-1586-449E-940C-E780590DE07CQ36254803-AFB35DE5-8D61-44D6-A6F5-2B547115BF9AQ36351000-1B5BF6E1-326E-48B9-A698-7F3F7AFB89C5Q36619998-49A5EBD0-5C2E-456E-86E0-4944D595E5C9Q37026980-E6CC924D-BCC2-4F02-9302-DE64D8400F4AQ37209498-96B85BD5-2018-47F4-BC69-8DE030E5E9D4Q37355067-2EE6489E-87B7-45BD-8250-079B2040150FQ37586327-32C28A0A-370C-4A68-8DEE-180D2B386038Q37619736-6647AF99-5426-4CF8-A6BF-0E178E41B519Q37979126-C1766856-A7DF-4B71-BA3D-B2E0D6FAB36FQ38292889-1663CB4F-3EE6-4C3E-80D5-38BDBBFB8526Q38667417-29BA597C-126C-4E72-A016-3368973348EAQ39042908-D9D23D7C-A719-4731-8BB0-354619898CD3Q39408153-CC806664-8891-4670-BE0B-479E039C1F15Q39719216-B6221A51-98B3-4CCA-8051-7BF84F56FCDDQ40013283-6B457EC2-CF09-4AEC-90B7-C0B0C1D09C5BQ40169511-C105E835-11ED-44D6-A8FE-DD158B617C44Q40401317-2D22F61A-C89C-4D0F-978D-D54C6120F791Q40593994-72D25A05-3BD1-45F0-93A3-E6C187640F9BQ40777976-C03BEEB1-292E-4FD1-B652-0FD69A73201CQ40902829-4E57BEE8-D542-47F4-BE04-FB77EEED0712
P2860
Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Increased gene-specific repair ...... man ovarian cancer cell lines.
@ast
Increased gene-specific repair ...... man ovarian cancer cell lines.
@en
type
label
Increased gene-specific repair ...... man ovarian cancer cell lines.
@ast
Increased gene-specific repair ...... man ovarian cancer cell lines.
@en
prefLabel
Increased gene-specific repair ...... man ovarian cancer cell lines.
@ast
Increased gene-specific repair ...... man ovarian cancer cell lines.
@en
P2093
P2860
P356
P1476
Increased gene-specific repair ...... man ovarian cancer cell lines.
@en
P2093
Link CJ Jr
O'Connor PM
P2860
P304
P356
10.1128/MCB.12.9.3689
P407
P577
1992-09-01T00:00:00Z